Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

키워드

참고문헌 (8)

1. Kyung-Soo Kim, "Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(4), pp.430~443 (2020), 대한간학회[DOI]
2. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
3. Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
4. Weinberg EM, "Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and co-morbid diseases", Clin Gastroenterol Hepatol (2020)[DOI]
5. Golabi P, "Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality", Clin Diabetes, 37, pp.65~72 (2019)
6. Golabi P, "Mortality of NAFLD according to the body composition and presence of metabolic abnormalities", Hepatol Commun, 4, pp.1136~1148 (2020)
7. Zelniker TA, "Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2diabetes mellitus", Circulation, 139, pp.2022~2031 (2019)
8. Ipsen DH, "Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis", Basic Clin Pharmacol Toxicol, 123, pp.704~713 (2018)

관련 논문AI추천